WGS Form 144: 29,283 Shares Proposed Sale; Recent Insider Sales $3.15M

Rhea-AI Filing Summary

Form 144 notice for GeneDx Holdings Corp. (WGS) shows proposed and recent sales of Class A Common Stock by an individual identified in the filing. Two broker-assisted proposed sales are reported for 09/30/2025: 16,425 shares through Morgan Stanley Smith Barney (aggregate market value $1,769,600) and 12,858 shares through Merrill Lynch (aggregate market value $1,390,912). The filing lists the securities as acquired by the seller as restricted stock units on 05/02/2022, 12/09/2022 and 04/26/2023, with acquisition amounts of 3,902, 6,575 and 18,806 shares respectively.

The filing also discloses actual sales by Katherine Stueland during the past three months totaling 29,189 shares for gross proceeds of $3,148,332. The company outstanding share count reported in the notice is 28,726,248, and the proposed combined aggregate market value of the planned sales is $3,160,512.

Positive

• Transparent disclosure of acquisition dates, nature of acquisition (Restricted Stock Units), broker names, and aggregate market values
• Detailed record of recent sales in the past three months including dates, amounts, and gross proceeds

Negative

• Significant insider selling reported (29,189 shares sold in past three months with $3,148,332 gross proceeds), which may be viewed negatively by some investors
• Extract lacks visible signature/date fields in the provided content, so the filing excerpt may be incomplete for confirming attestations

Insights

Securities Analyst

TL;DR: Routine insider sale disclosure; transaction sizes are modest relative to total shares outstanding.

The filing is a standard Rule 144 notice disclosing proposed brokered sales and recent transactions by an insider. It provides clear acquisition history (restricted stock units) and lists broker names and aggregate market values. Recent realized sales of 29,189 shares produced $3.15 million in proceeds, and planned sales of 29,283 shares total $3.16 million. For investors, this is transparent disclosure of insider liquidity but does not by itself indicate a change in company fundamentals.

Compliance & Risk Analyst

TL;DR: Filing appears compliant and complete for Rule 144 reporting; signatures/plan adoption dates are not shown in the extract.

The notice includes required detail on acquisition dates, nature of acquisition (RSUs), broker identities and transaction amounts, which supports Rule 144 compliance. The factual statements include an attestation about material nonpublic information, but the extract does not display a signed signature block or a date of notice in the provided content. If present in the full filing, those items would complete the record; their absence in this extract is a gap in the provided text.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Morgan Stanley Smith Barney 2000 Westchester Avenue Purchase NY 10577	16425	1769600	28726248	09/30/2025	NASDAQ
Class A Common Stock	Merrill Lynch 2049 Century Park E Ste 1200 Los Angeles CA 90067	12858	1390912	28726248	09/30/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	05/02/2022	Acquired as compensation - Restricted Stock Units	Issuer			3902	05/02/2022	Compensation
Class A Common Stock	12/09/2022	Acquired as compensation - Restricted Stock Units	Issuer			6575	12/09/2022	Compensation
Class A Common Stock	04/26/2023	Acquired as compensation - Restricted Stock Units	Issuer			18806	04/26/2023	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Katherine Stueland 333 Ludlow St, North Tower 6th Floor Stamford CT 06902	Class A Common Stock	07/01/2025	9657	878181
Katherine Stueland 333 Ludlow St, North Tower 6th Floor Stamford CT 06902	Class A Common Stock	07/09/2025	3220	299460
Katherine Stueland 333 Ludlow St, North Tower 6th Floor Stamford CT 06902	Class A Common Stock	07/29/2025	2154	226838
Katherine Stueland 333 Ludlow St, North Tower 6th Floor Stamford CT 06902	Class A Common Stock	09/09/2025	3657	468297
Katherine Stueland 333 Ludlow St, North Tower 6th Floor Stamford CT 06902	Class A Common Stock	09/16/2025	10501	1275556

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for GeneDx Holdings Corp. (WGS) report?

The filing reports proposed brokered sales of 16,425 and 12,858 Class A shares for 09/30/2025 and recent insider sales of 29,189 shares totaling $3,148,332 in gross proceeds.

Who conducted the brokered sales listed in the Form 144?

The proposed sales list Morgan Stanley Smith Barney and Merrill Lynch as the brokers for the 09/30/2025 transactions.

How were the securities acquired that are now being sold?

The securities were acquired as compensation (Restricted Stock Units) on 05/02/2022 (3,902 shares), 12/09/2022 (6,575 shares) and 04/26/2023 (18,806 shares).

What are the total outstanding shares referenced in the filing?

The notice reports 28,726,248 shares outstanding for the Class A Common Stock.

How much aggregate market value is shown for the proposed 09/30/2025 sales?

The combined aggregate market value shown for the two proposed sales is $3,160,512.